|Videos|November 16, 2022

Dr. Siefker-Radtke discusses current research on the use of erdafitinib to treat urothelial carcinoma

"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.

Arlene O. Siefker-Radtke, MD, is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. In this interview, Siefker-Radtke discusses the ongoing trials on the use of erdafitinib to treat FGFR3 altered urethelial cancers. She was interviewed during the 2022 LUGPA Annual Meeting in Chicago, Illinois.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more